Sung Hoon Kang, Jee Hyang Jeong, Jung-Min Pyun, Geon Ha Kim, Young Ho Park, YongSoo Shim, Seong-Ho Koh, Chi-Hun Kim, Young Chul Youn, Dong Won Yang, Hyuk-Je Lee, Han Lee, Dain Kim, Kyunghwa Sun, So Young Moon, Kee Hyung Park, Seong Hye Choi
{"title":"韩国莱卡耐单抗治疗的资格：来自记忆诊所的真实世界数据","authors":"Sung Hoon Kang, Jee Hyang Jeong, Jung-Min Pyun, Geon Ha Kim, Young Ho Park, YongSoo Shim, Seong-Ho Koh, Chi-Hun Kim, Young Chul Youn, Dong Won Yang, Hyuk-Je Lee, Han Lee, Dain Kim, Kyunghwa Sun, So Young Moon, Kee Hyung Park, Seong Hye Choi","doi":"10.3988/jcn.2024.0550","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>We aimed to determine the proportion of Korean patients with early Alzheimer's disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.</p><p><strong>Methods: </strong>We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.</p><p><strong>Results: </strong>When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.</p><p><strong>Conclusions: </strong>Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.</p>","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 3","pages":"182-189"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056135/pdf/","citationCount":"0","resultStr":"{\"title\":\"Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics.\",\"authors\":\"Sung Hoon Kang, Jee Hyang Jeong, Jung-Min Pyun, Geon Ha Kim, Young Ho Park, YongSoo Shim, Seong-Ho Koh, Chi-Hun Kim, Young Chul Youn, Dong Won Yang, Hyuk-Je Lee, Han Lee, Dain Kim, Kyunghwa Sun, So Young Moon, Kee Hyung Park, Seong Hye Choi\",\"doi\":\"10.3988/jcn.2024.0550\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and purpose: </strong>We aimed to determine the proportion of Korean patients with early Alzheimer's disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.</p><p><strong>Methods: </strong>We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.</p><p><strong>Results: </strong>When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.</p><p><strong>Conclusions: </strong>Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.</p>\",\"PeriodicalId\":15432,\"journal\":{\"name\":\"Journal of Clinical Neurology\",\"volume\":\"21 3\",\"pages\":\"182-189\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056135/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3988/jcn.2024.0550\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3988/jcn.2024.0550","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics.
Background and purpose: We aimed to determine the proportion of Korean patients with early Alzheimer's disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.
Methods: We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.
Results: When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.
Conclusions: Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.
期刊介绍：
The JCN aims to publish the cutting-edge research from around the world. The JCN covers clinical and translational research for physicians and researchers in the field of neurology. Encompassing the entire neurological diseases, our main focus is on the common disorders including stroke, epilepsy, Parkinson''s disease, dementia, multiple sclerosis, headache, and peripheral neuropathy. Any authors affiliated with an accredited biomedical institution may submit manuscripts of original articles, review articles, and letters to the editor. The JCN will allow clinical neurologists to enrich their knowledge of patient management, education, and clinical or experimental research, and hence their professionalism.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
